StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen GAAP R&D Expense as % of Product Sales by Year

GAAP R&D Expense as % of Product Sales (%) (%)

Amgen GAAP R&D Expense as % of Product Sales: 20.7% in FY2025, up 2.1 pts from a year earlier. That is the highest of the 9 years on record here.

Latest, FY2025
20.7%
Period ended Dec 31, 2025
Change on a year earlier
+2.1 pts
18.6% in FY2024
History
9 years
Since FY2017
Sources
8
Documents cited below

Where the FY2025 figure comes from

“|| GAAP research and development expenses as a percentage of product sales | 22.9 | % | 19.8 | % | 20.7 | % | 18.6 | %”

Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗

Reported in Form 8-K Reconciliations of GAAP to Non-GAAP Measures.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Amgen GAAP R&D Expense as % of Product Sales (%), annual FY2017–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gaap-rd-pct

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.